BioCentury
ARTICLE | Clinical News

Tanzeum albiglutide regulatory update

April 21, 2014 7:00 AM UTC

FDA approved Tanzeum albiglutide from GlaxoSmithKline to treat Type II diabetes as monotherapy or as add-on therapy. GSK plans to launch Tanzeum in the U.S. next quarter, but declined to comment on pr...